{"id":18599,"date":"2023-04-22T13:17:02","date_gmt":"2023-04-22T07:47:02","guid":{"rendered":"https:\/\/www.moneyworks4me.com\/investmentshastra\/?p=18599"},"modified":"2023-05-08T16:39:58","modified_gmt":"2023-05-08T11:09:58","slug":"mankind-pharma-ipo-review","status":"publish","type":"post","link":"https:\/\/www.moneyworks4me.com\/investmentshastra\/mankind-pharma-ipo-review\/","title":{"rendered":"Mankind Pharma IPO Review"},"content":{"rendered":"
\n

Mankind Pharma Limited IPO Details:<\/h2>\n

Estimated Market Cap 43,264 Cr<\/strong><\/p>\n

IPO Date:<\/strong> 25th April to 27th April<\/p>\n

Total shares:<\/strong> 4.00 Cr<\/p>\n

Price band:<\/strong> \u20b9. 1026- \u20b9. 1080 per share<\/p>\n

IPO Issue Size:<\/strong> ~ \u20b9. 4326.36 Cr<\/p>\n

Lot Size:<\/strong> 13 shares and multiples thereof<\/p>\n

Purpose of IPO:<\/strong> Offer for sale by existing shareholders<\/p>\n

Recommendation:<\/strong>  Subscribe <\/strong><\/span>(Aggressive investors)<\/p>\n<\/div>\n

About Mankind Pharma:<\/h2>\n

Mankind Pharma<\/strong><\/a> is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic<\/strong> areas, as well as several consumer healthcare products. According to companies, DRHP Mankind is India\u2019s fourth-largest pharmaceutical company <\/strong>in terms of Domestic Sales and second-largest<\/strong> in terms of sales volume for the Financial Year 2022.<\/p>\n

Mankind Pharma has a strong focus on the domestic market, with revenue from operations in India accounting for 97.60<\/strong> %<\/strong> of its total revenue in the financial year 2022. The company has developed 36 brands<\/strong> in the pharmaceutical business and boasts one of the largest networks of medical representatives in the Indian pharmaceutical market.<\/p>\n

Portfolio of the company in key therapeutic and Revenue breakup from domestic Sales<\/strong><\/p>\n

\"\"<\/a><\/p>\n

Company\u2019s highest-selling pharmaceutical brands<\/strong><\/p>\n

\"pharmaceutical<\/a>Financial:<\/h2>\n

Mankind Pharma has shown consistent revenue growth over the years. The company’s revenue has grown at a CAGR of 15.7% over the last five years.<\/p>\n

\"value<\/a>
Source-MoneyWorks4Me, Company Data<\/figcaption><\/figure>\n

The company’s return on equity (ROE) has also been consistently above 20% over the last five years.<\/p>\n

\"key<\/a>
Source-MoneyWorks4Me, Company Data<\/figcaption><\/figure>\n

Sales growth is well complemented by EPS growth, which indicates that the company is becoming more efficient in generating profits from its sales. This could be due to a variety of reasons, including cost-cutting measures, price increases, or an increase in sales of higher-margin products.<\/p>\n

\"cagr\"<\/a>
Source-MoneyWorks4Me, Company Data<\/figcaption><\/figure>\n

Key Financial Ratios and Trends:<\/h2>\n
\"key<\/a>
Source-MoneyWorks4Me, Company Data<\/figcaption><\/figure>\n

Management:<\/h2>\n

Ramesh Juneja <\/strong>is the Chairman and a Whole-Time Director of our Company. He is a founder and Promoter of our Company. He has been associated with our Company since its incorporation as a Director and Promoter. He does not hold any formal educational qualifications. He has experience of over 31 years in the pharmaceutical industry. <\/p>\n

Rajeev Juneja<\/strong> is the Vice-Chairman and Managing Director of our Company. He is also a Promoter of our Company and has been associated with our Company since December 22, 1992. He does not hold any formal educational qualifications. He has experience of over 29 years in the pharmaceutical industry.<\/p>\n

Sheetal Arora<\/strong> is the Chief Executive Officer and a Whole-Time Director of our Company. He is also a Promoter of our Company and has been associated with our Company since September 21, 2007. He holds a bachelor\u2019s degree in commerce from the Srikrishnadevaraya University, Anantapur. He has experience of over 14 years in the pharmaceutical industry.<\/p>\n

Positives:<\/strong><\/p>\n